Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Net Cash Flow: 2015-2025

Historic Net Cash Flow for Assembly Biosciences (ASMB) over the last 11 years, with Sep 2025 value amounting to -$1.5 million.

  • Assembly Biosciences' Net Cash Flow fell 115.92% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.9 million, marking a year-over-year decrease of 429.51%. This contributed to the annual value of $18.5 million for FY2024, which is 156.80% up from last year.
  • As of Q3 2025, Assembly Biosciences' Net Cash Flow stood at -$1.5 million, which was down 348.23% from $593,000 recorded in Q2 2025.
  • Over the past 5 years, Assembly Biosciences' Net Cash Flow peaked at $18.8 million during Q1 2021, and registered a low of -$25.1 million during Q4 2021.
  • For the 3-year period, Assembly Biosciences' Net Cash Flow averaged around -$2.7 million, with its median value being -$1.1 million (2024).
  • Within the past 5 years, the most significant YoY rise in Assembly Biosciences' Net Cash Flow was 526.90% (2021), while the steepest drop was 2,318.27% (2021).
  • Over the past 5 years, Assembly Biosciences' Net Cash Flow (Quarterly) stood at -$25.1 million in 2021, then spiked by 91.03% to -$2.3 million in 2022, then crashed by 202.22% to -$6.8 million in 2023, then surged by 245.15% to $9.9 million in 2024, then plummeted by 115.92% to -$1.5 million in 2025.
  • Its Net Cash Flow was -$1.5 million in Q3 2025, compared to $593,000 in Q2 2025 and -$14.9 million in Q1 2025.